TY - JOUR T1 - Forecast of the COVID-19 outbreak, collapse of medical facilities, and lockdown effects in Tokyo, Japan JF - medRxiv DO - 10.1101/2020.04.02.20051490 SP - 2020.04.02.20051490 AU - Junko Kurita AU - Tamie Sugawara AU - Yasushi Ohkusa Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/16/2020.04.02.20051490.abstract N2 - Background The number of patients of COVID-19 in Tokyo has been increasing gradually through the end of March, 2020.Object Support for policymaking requires forecasting of the entire course and outcome of the outbreak including the date of collapse of medical facilities if a lockdown is not initiated. Moreover, the effects of a lockdown must be considered when choosing to initiate one.Method Data of Tokyo patients with symptoms during January 14 – March 28, 2020 were used to formulate a susceptible–infected–recovered (SIR) model using three age classes and to estimate the basic reproduction number (R0). Based on the estimated R0, We inferred outbreak outcomes including the date of collapse of medical facilities if a lockdown were not enacted. Then we estimate the lockdown effects.Results Results suggest R0 as 2.86, with a 95% confidence interval of [2.73, 2.97]. Collapse of medical facilities can be expected to occur on April 26 if no lockdown occurs. The total number of deaths can be expected to be half a million people. If a lockdown were enacted from April 6, and if more than 60% of trips outside the home were restricted voluntarily, then a collapse of medical facilities could be avoided.Discussion and Conclusion The estimated R0 was similar to that found from other studies conducted in China and Japan. Results demonstrate that a lockdown with reasonable cooperation of residents can avoid a collapse of medical facilities and save 0.25 million mortality cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases of Domestic Situation (in Japanese) https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00086.html ER -